
    
      To compare, as a preliminary analysis, the effects of subcutaneously administered MEDI-522
      versus placebo at 6 months on disease activity and progression of structural joint damage in
      patients with rheumatoid arthritis (RA), who have active disease despite ongoing treatment
      with methotrexate (MTX) with or without hydroxychloroquine (HCQ) and/or sulfasalazine (SSZ).
    
  